CV Sciences (CVSI) Cash from Operations (2011 - 2026)
CV Sciences (CVSI) reported Cash from Operations of 101000.0 for Q1 2026, up 224.69% on a YoY basis from 31106.46 in Q1 2025, and up 133.67% sequentially from 300000.0 in Q4 2025.
CV Sciences (CVSI) Cash from Operations (2011 - 2026) Analysis & Trends
CV Sciences (CVSI) has 16 years of Cash from Operations data on file, last reported at 101000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Operations rose 224.69% year-over-year to 101000.0; the trailing twelve-month figure through Mar 2026 stood at 218000.0 (up 48.58% YoY), and the FY2025 full-year result was 400000.0, up 53.54% from the prior year.
- Cash from Operations rose to 101000.0 in Q1 2026, from 300000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 1411000.0 in Q2 2023 to a low of 1169000.0 in Q2 2022.
- A 5-year average of 46588.24 and a median of 114000.0 in 2023 frame the typical range for Cash from Operations.
- Across the five-year window, Cash from Operations tumbled 542.11% in 2024 and jumped 603.51% in 2025, its largest moves.
- Tracing CVSI's Cash from Operations over 5 years: stood at 210000.0 in 2022, then sank by 154.29% to 114000.0 in 2023, then tumbled by 43.86% to 164000.0 in 2024, then sank by 82.93% to 300000.0 in 2025, then soared by 133.67% to 101000.0 in 2026.
- Business Quant data shows CVSI's Cash from Operations at 101000.0 in Q1 2026, 300000.0 in Q4 2025, and 306000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -40.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 401.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 463.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 388.30 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 145.80 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 13.00 Mn |
| 10 | CV Sciences | 3.74 Mn | 3.43 Mn | 1.56 Mn | 101,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 101,000.00 |
| Mar 31, 2026 | 101,000.00 |
| Dec 31, 2025 | -300,000.00 |
| Dec 31, 2025 | -300,000.00 |
| Sep 30, 2025 | -306,000.00 |
| Sep 30, 2025 | -306,000.00 |
| Jun 30, 2025 | 287,000.00 |
| Jun 30, 2025 | 287,000.00 |
| Mar 31, 2025 | -81,000.00 |
| Mar 31, 2025 | -81,000.00 |
| Dec 31, 2024 | -164,000.00 |
| Dec 31, 2024 | -164,000.00 |
| Sep 30, 2024 | -122,000.00 |
| Sep 30, 2024 | -122,000.00 |
| Jun 30, 2024 | -57,000.00 |
| Jun 30, 2024 | -57,000.00 |
| Mar 31, 2024 | -518,000.00 |
| Mar 31, 2024 | -518,000.00 |
| Dec 31, 2023 | -114,000.00 |
| Dec 31, 2023 | -114,000.00 |